RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. RIBBON-2 results demonstrated that adding bevacizumab to chemotherapy as a second-line treatment for metastatic breast cancer significantly improved progression-free survival. Official San Antonio Breast Cancer Symposium press conference.